Blog
About


  • Record: found
  • Abstract: found
  • Article: found
Is Open Access

Management of Hypertension: JNC 8 and Beyond

Read Bookmark

Abstract

Hypertension is a leading risk factor for cardiovascular disease, the leading cause of death and morbidity in our society and on a global scale. Major components of cardiovascular disease include stroke, coronary artery disease, heart failure, and chronic kidney disease, in all of which hypertension plays a major role. The risk of these complications increases directly and linearly with systolic blood pressure starting at 115 mmHg. Although usually asymptomatic, hypertension is readily detectable on physical examination and is amenable to both lifestyle modification and pharmacologic treatment in most patients. However, large proportions of the hypertensive population remain undetected and undertreated. Numerous guidelines have been issued during the past few decades to promote detection and optimal therapy. Despite the increase in risk with systolic blood pressure greater than 115 mmHg, the generally accepted threshold for diagnosis and treatment has been systolic blood pressure greater than 139 mmHg and diastolic blood pressure greater than 80 mmHg because until recently treatment to lower levels has been associated with an unfavorable relation between clinical benefit and harm. In the past several years, new guidelines, advisories, commentaries, and clinical trials have provided evidence for a potential change in current recommendations for the management of hypertension. In this regard, the long-awaited eighth report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommended patients older than 60 years be treated to a systolic blood pressure of less than 150 mmHg, which has generated considerable controversy and caution. The striking findings of the Systolic Blood Pressure Intervention Trial (SPRINT) have received considerable attention because of the demonstration that intensive therapy to a target systolic blood pressure below 120 mmHg decreases cardiovascular mortality and morbidity more than less intensive treatment to a target systolic blood pressure below 140 mmHg, but this approach is not fully generalizable because the trial excluded patients younger than 50 years and those with diabetes and prior stroke. This article addresses major issues in the management of hypertension, including those in the seventh and eight reports of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and subsequent studies, considering maintenance of prior standards as well as the potential application of important new findings.

Related collections

Most cited references 13

  • Record: found
  • Abstract: not found
  • Article: not found

A randomized trial of intensive versus standard blood-pressure control

  • Record: found
  • Abstract: not found
  • Article: not found

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

  • Record: found
  • Abstract: not found
  • Article: not found

Generalizability of SPRINT results to the U.S

Author and article information

Affiliations
1Division of Cardiovascular Medicine, Department of Internal Medicine, University of California, Davis, School of Medicine, Sacramento, CA 95817, USA
Author notes
Correspondence: Ezra A. Amsterdam, MD, University of California, Davis, School of Medicine, Ellison Building, 4860 Y Street, Sacramento, CA 95817, USA, Tel.: +1-916-7345191, E-mail: eaamsterdam@123456ucdavis.edu
Journal
CVIA
Cardiovascular Innovations and Applications
CVIA
Compuscript (Ireland)
2009-8782
2009-8618
September 2016
October 2016
: 1
: 4
: 409-416
Copyright © 2016 Cardiovascular Innovations and Applications

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License (CC BY-NC 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc/4.0/.

Product
Categories
REVIEWS

Comments

Comment on this article